Scholarlink

<p>Anticancer therapy, encompassing systemic therapies such as chemotherapy, targeted therapy, and immunotherapy, as well as radiotherapy, can induce neutropenia. This condition is a frequent hematological adverse event and a dose-limiting toxicity. Neutropenia can cause interruptions or delays in anticancer therapy, febrile neutropenia, and serious infections, which in turn raises treatment costs, reduces therapeutic efficacy, and may even lead to life-threatening complications. Consequently, accurately assessing the risk of neutropenia, promptly identifying febrile neutropenia and infections, and implementing appropriate preventive and therapeutic measures are crucial for mitigating anticancer therapy-related complications, enhancing the safety and effectiveness of anticancer therapy. Grounded in evidence-based medicine and expert consensus, the Committee of Neoplastic Supportive-Care (CONS) of the China Anti-Cancer Association has developed these guidelines to assist clinical oncologists in managing neutropenia resulting from anticancer therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CACA guidelines for managing cancer therapy-induced neutropenia (2026)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月21日

查看全文
  • Li Xiao,
  • Fenghua Wang,
  • Ying Yuan,
  • Shu Xia,
  • Wenxing Qin,
  • Xiaotian Zhang,
  • Yanhong Deng,
  • Xianglin Yuan,
  • Yi Ba,
  • Jun Zhang

摘要

Anticancer therapy, encompassing systemic therapies such as chemotherapy, targeted therapy, and immunotherapy, as well as radiotherapy, can induce neutropenia. This condition is a frequent hematological adverse event and a dose-limiting toxicity. Neutropenia can cause interruptions or delays in anticancer therapy, febrile neutropenia, and serious infections, which in turn raises treatment costs, reduces therapeutic efficacy, and may even lead to life-threatening complications. Consequently, accurately assessing the risk of neutropenia, promptly identifying febrile neutropenia and infections, and implementing appropriate preventive and therapeutic measures are crucial for mitigating anticancer therapy-related complications, enhancing the safety and effectiveness of anticancer therapy. Grounded in evidence-based medicine and expert consensus, the Committee of Neoplastic Supportive-Care (CONS) of the China Anti-Cancer Association has developed these guidelines to assist clinical oncologists in managing neutropenia resulting from anticancer therapy.